Related Experiment Video
Updated: Aug 31, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Uric acid lowering for slowing CKD progression after the CKD-FIX trial: a solved question or still a dilemma?
Giovanna Leoncini1, Cecilia Barnini1, Luca Manco1
1Department of Internal Medicine, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Insights
Hyperuricemia is linked to kidney disease, but urate-lowering treatments like allopurinol show no clear kidney benefits. Further research is needed to understand uric acid
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Pharmacology
Background:
- Hyperuricemia is associated with cardiovascular risks and kidney disease.
- Uric acid may contribute to renal haemodynamic and tissue damage.
- Urate-lowering therapies are explored for kidney protection.
Purpose of the Study:
- To critically review literature on urate-lowering treatments and renal outcomes.
- To interpret recent trial results regarding nephroprotection.
- To evaluate the role of xanthine oxidase inhibitors in kidney health.
Main Methods:
- Literature review of in vitro studies, animal models, and clinical trials.
- Critical analysis of randomized controlled trials involving allopurinol and febuxostat.
- Interpretation of intervention trial data on urate-lowering treatments.
Main Results:
- In vitro and animal studies suggest uric acid's role in renal damage.
- Recent randomized controlled trials did not demonstrate renal benefits from allopurinol or febuxostat.
- Evidence for urate-lowering therapy improving nephroprotection remains inconclusive.
Conclusions:
- Current evidence casts doubt on the efficacy of allopurinol and febuxostat for nephroprotection.
- The role of urate-lowering treatment in improving kidney outcomes requires further investigation.
- Re-evaluation of the therapeutic approach for hyperuricemia-related kidney disease is warranted.
Abstract:
Hyperuricemia has been associated with several cardiovascular risk factors and is a well-known predictor of kidney disease. In vitro studies as well as animal models highlighted a role for uric acid in the development and progression of haemodynamic and tissue damage at the renal level leading to glomerular and tubulointerstitial abnormalities. Urate-lowering treatment, especially by xanthine oxidase inhibitors, has been proposed in order to improve kidney outcomes. However, recent randomized controlled trials failed to demonstrate a beneficial effect of allopurinol or febuxostat on renal disease, casting doubts on the role of this therapeutical approach to improve nephroprotection. We provide a critical overview of current literature on this topic and offer a possible interpretation of results from recent intervention trials with urate-lowering treatment on renal outcomes.
More Related Videos
10:02Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
Published on: October 3, 2020
04:37Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
Published on: April 25, 2025
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Urinary Tract Calculi III: Medical Management
Chronic Kidney Disease I: Introduction
Urinary Tract Calculi IV: Nutrition Therapy and Prevention